We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

News · September 19, 2022

EADV 2022: Post-Hoc Analysis Shows Roflumilast Effective and Safe by Racial and Ethnic Subgroups in Seborrheic Dermatitis

The highly potent phosphodiesterase-4 inhibitor significantly improved disease severity, erythema, scaling, and itch

PracticeUpdate Editorial Team


Further Reading